Related Experiment Video
Updated: Aug 11, 2026
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
PCV chemotherapy for recurrent glioblastoma
F Schmidt1, J Fischer, U Herrlinger
1Department of General Neurology, Hertie Institute for Clinical Brain Research, University of Tuebingen, Medical School, Tuebingen, Germany. friederike.schmidt@uni-tuebingen.de
Abstract:
The authors administered procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU, lomustine), and vincristine (PCV) to 86 patients with recurrent glioblastoma. There were three partial responses, but no complete responses. Median progression-free survival was 17.1 weeks and progression-free survival at 6 months was 38.4%. World Health Organization grade III/IV hematologic toxicity was common (25.6%), but nonhematologic toxicity was mild.
